儿童高级心力衰竭患者的家庭米利诺疗法:加拿大单一中心体验
Ahmed A Hassan1, Aamir Jeewa1, Lujayn Mahmoud1
1Labatt Family Heart Centre, Division of Cardiology, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
CJC pediatric and congenital heart disease
|April 2, 2025
概括
家庭密里诺治疗 (HMT) 安全地支持患有末期心力衰竭 (ESHF) 的儿童,使他们能够返回家园. 这种治疗是有效的桥梁儿童患者心脏移植或恢复.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 心血管外科心血管外科
- 药理学 药理学是指药理学的学科.
背景情况:
- 末期心力衰竭 (ESHF) 是儿科心脏移植的主要指示.
- 优化的口服心力衰竭 (HF) 药物对一些儿童来说是不够的,需要先进的支持.
- 连续静脉注射的米利诺因已被用作桥梁,在儿科患者中进行移植.
研究的目的:
- 审查和报告家庭米利诺治疗 (HMT) 计划的安全性和结果.
- 评估HMT在患有ESHF的儿科患者中的疗效.
- 评估与HMT相关的再住院率,并发症和整体结果.
主要方法:
- 单中心,回顾性队列研究.
- 包括2001年至2022年期间在HMT上出院的儿科患者.
- 从SickKids HF数据库收集数据,重点关注再住院,并发症和治疗结果.
主要成果:
- 36名儿科患者开始接受HMT (平均年龄为3.6岁).
- HMT主要用作移植 (58%),康复/候选人 (22%),息治疗 (17%) 和手术修复 (3%) 的桥梁.
- 67%的患者被重新录取,主要原因是中枢线问题 (35%) 和恶化高血压 (32%);没有与高血压直接相关的死亡.
结论:
- 家庭米利诺治疗 (HMT) 是对儿科ESHF的安全有效的支持策略.
- HMT有助于重症心力衰竭儿童过渡到家庭环境.
- 这种方法可以成功地将儿科患者连接到心脏移植或其他康复途径.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
445
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
445
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331